Kornimate/medical-research-clean huggingface dataset:
effect of cranial stimulation and acupuncture on pain, functional capability and cerebral function in osteoarthritis

Conditions: Osteoarthritis, Knee; Chronic Pain

Summary: the objective of this study is to evaluate the efficacy of transcranial direct current stimulation (tdcs) and electro acupuncture (eac) compared to sham treatment in reducing pain, improving functional capacity and functioning of the neuro-immune-endocrine system in patients with chronic pain due to knee osteoarthritis.

the knee osteoarthritis has high prevalence, which tends to increase with the aging population. the limited efficacy of pharmacological interventions stimulates the search for other options, in order to increase the therapeutic success. acupuncture is widely used for pain control in several pathologies. a modality of intramuscular stimulation to quantify the intensity of the stimulus is electro acupuncture (eac) that the intensity of 2 hz accelerates the release of enkephalins, endorphins and beta-endorphins. the application of electric currents to modify brain function is a very old technique. the transcranial direct current stimulation (tdcs) is based on applying transcranial direct weak current (usually above 2ma) through electrodes in a non-invasive, simple and painless. other advantages include low cost and the possibility of a placebo reliable. the purpose of this study is to evaluate the ability to reduce pain and improve functionality in chronic pain for knee osteoarthritis with two techniques, one that promotes a bottom-up approach (eac) and other top-down (tdcs). we will seek to analyze the efficacy of them separately and together, seeking summation of results.

Eligibility criteria:
inclusion criteria:- provision of informed consent to participate. * women with over 18 years old,with chronic pain because of primary osteoarthritis of the knee. * pain stable for at least three months. score greater than or equal to 3 cm (0 cm = "no pain" and "worst possible pain" = 10cm) on visual analog scale (vas) for pain perception at baseline. * no contraindications to electroacupuncture, transcranial direct current stimulation or transcranial magnetic stimulation. exclusion criteria:-clinically significant or unstable disorder, medical or psychiatric. * presence of neurological or rheumatic comorbidity. * pregnancy. * already having been treated with acupuncture. * having performed with corticosteroid infiltration in the last six weeks or are using this. * having performed with hyaluronic acid infiltration in the last year. * previous surgery on the limb to be treated or have surgical program for the next 6 months.

Keywords: electro acupuncture knee osteoarthritis chronic pain cortical excitability
phase 1, dose-escalation study of ign002 in nhl subjects

Conditions: Non-Hodgkin Lymphoma

Summary: a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of multiple intravenous doses of ign002 administered weekly to subjects with refractory non-hodgkin lymphoma (nhl)

this open-label, non-randomized, first-in-human phase 1 study involves two stages: in the dose-escalation stage, ascending dose cohorts will be treated in 2 periods until the maximum tolerated dose is identified. in period 1, subjects will receive 2 doses of ign002 administered weekly. in period 2, subjects will receive up to 24 additional doses of ign002 administered weekly in three 8-week cycles. subjects that have not progressed following the treatment period will be followed for another 6 months. in the expansion stage, subjects will receive up to 24 doses of ign002 at the identified maximum tolerated dose administered weekly in three 8-week cycles. subjects that have not progressed following the treatment period will be followed for another 6 months.

Eligibility criteria:
inclusion criteria: * documented history of immunohistochemistry (ihc)-confirmed cd20-positive (with no subsequent history of cd20-negativity) b-cell, nhl, including diffuse large b cell (dlbcl), mantle cell, marginal zone, lymphoplasmacytic, follicular, transformed follicular, or primary mediastinal b cell lymphoma * refractory disease, having failed available therapies * measurable disease * eastern cooperative oncology group (ecog) performance status of 0-2 * life expectancy \> 3 months * adequate organ function exclusion criteria: * treatment with an approved or investigational chemotherapy drug within 28 days of day 1 * treatment with an approved or investigational anti-cd20 drug within 28 days of day 1 * treatment with an approved or investigational biologic drug that does not target cd20 within 90 days of day 1 * radiation therapy within 4 weeks of day 1
inhibition of α-synuclein cell-cell transmission by nmdar blocker, memantine

Conditions: Parkinson Disease

Summary: lewy body dementia (lbd), is the second most common form of dementia after alzheimer's disease. dementia is defined as a serious loss in cognitive ability due to damages or disease in the brain beyond what is normal aging. with lewy body dementia, protein deposits, or lewy bodies, accumulate in nerve cells throughout the brain, affecting motor control, memory and thinking. lbd can also form with the progression of parkinson's disease (pd). pd is a degenerative nervous system disorder that affects movement ability. using more sensitive mri imaging techniques the investigators are attempting to see if disease progression can be monitored more closely. at the same time, the study medication memantine will be compared to a placebo to determine if it can be used to slow the progression of pd. the purpose of this study is to assess if disease progression can be better monitored through brain imaging and if memantine will help slow disease progression.


Eligibility criteria:
inclusion criteria: 1. diagnosed with idiopathic pd for at least 2 or more years 2. 45 to 85 years of age 3. have been on stable doses of anti-parkinson medication 4. able to give informed consent 5. able to undergo brain mri 6. unilateral symptoms 7. a score of 26 or greater on the montreal cognitive assessment (moca), a measure of a patients short-term memory recall, the ability to determine visual-spatial relationships of objects, attention, concentration, working memory, language and orientation to time and place 8. use of one method of medically approved contraceptive exclusion criteria: 1. history of any surgical intervention for treating pd (i.e. deep brain stimulation) 2. extreme physical disability 3. history or current diagnosis of unstable psychiatric condition 4. presence of dementia or any other condition that prevents the ability of the participant to provide fully informed consent 5. other brain disease 6. treatment with memantine 30 days prior to baseline 7. females who are pregnant or nursing 8. presence of interacting medications with memantine or co-morbid medical conditions that may be exacerbated by this agent 9. moderately significant drug interactions with dextromethorphan, amantadine, sodium bicarbonate, and acetazolamide 10. previous allergic reaction to memantine 11. any genetic form of pd
telerehabilitation protocols with digital and robotic tools for people with chronic neurological disorders

Conditions: Post-stroke; Parkinson Disease; Multiple Sclerosis

Summary: the goal of this clinical trial is to test an innovative telerehabilitation protocol in people with chronic neurological disorders (parkinson's disease, multiple sclerosis, and post-stroke). the main questions it aims to answer are 1)the usability and acceptability of the system; 2)the level of safety of intervention; 3) the efficacy of the telerehabilitation protocol. participants will be randomized (with an allocation ratio of 1:1) into either the experimental group (20 sessions of motor telerehabilitation with digital and robotic tools) or the active control group (20 motor rehabilitation sessions performed at home according to the usual care treatment procedure). researchers will compare the experimental group and the active control group to see if the tr protocol with digital and robotic tools is effective in reducing the perceived level of disability.


Eligibility criteria:
inclusion criteria: 1. diagnosis of chronic post-stroke condition with ischemic or haemorrhagic stroke injury occurred 4-6months before recruitment and with motor impairment of the upper limb \> 2 to the medical research council scale (mrc); or diagnosis of probable pd according to mds criteria (postuma et al., 2015) in staging between 1.5 and 3 on the hoehn \& yahr scale (goetz et al., 2004); or diagnosis of ms, rr-sp forms, according to the criteria of mc donald 2010 (polman et al., 2011) with disability level at the expanded disability status scale edss (kurtzke, 1983) \< 6; 2. age between 25 and 85 years; 3. preserved cognitive level at the montreal cognitive assessment test (moca test \>17.36) (conti et al., 2015); 4. agreement to participate with the signature of the informed consent form; 5. no rehabilitation program in place at the time of enrolment; 6. stable drug treatment (last 3 months) with l-dopa or dopamine agonists (pd group) and/or cortisone (ms group). exclusion criteria: 1. presence of comorbidities that might prevent patients from undertaking a safe home program or determining clinical instability (i.e., severe orthopedic or severe cognitive deficits); 2. presence of major psychiatric complications or personality disorders; 3. presence of severe impairment of visual and/or acoustic perception; 4. relapse ongoing/at least 3 months since the last relapse (ms group); 5. presence of "frequent" freezing as recorded at the administration of section ii (daily life activity) of the updrs (score ≥ 3) (pd group); 6. falls resulting in injuries or a number of falls ≤ 2 in the 6 months prior to recruitment (pd and ms groups).

Keywords: telerehabilitation digital medicine robotics chronic neurological conditions
epidural analgesia, beta-endorphin concentrations in colostrum, and infant neurobehavior as breast-feeding predictors

Conditions: Breastfeeding; Lactation; Analgesia

Summary: presently, the literature addressing the relationship between epidural analgesia and likelihood of breast-feeding is inconclusive. numerous studies have found that epidurals, administered prior to vaginal delivery of a full-term, healthy neonate, significantly decrease lactation success at follow-up times ranging from 24 hours to 6 months postpartum. one proposed mechanism is that analgesics, by decreasing maternal pain during labor, decrease maternal endorphin production and result in the transmission of lower endorphin levels to the neonate during breast-feeding. lower endorphin levels, in turn, may render the neonate less likely to suckle optimally. other studies have found that epidural analgesia does not significantly decrease lactation success when used during the vaginal delivery of a full-term, healthy neonate. although most studies to date have compared the breast-feeding success of epidural recipients and non-recipients at various points postpartum, they do not specifically note whether deficient feeding behaviors on the part of the infant contribute to failed breast-feeding. the present study uses the latch assessment tool to score the infant's ability to latch onto the breast and the presence of audible swallowing, as well as the mother's level of physical comfort with breast feeding, whether she can successfully position the infant for feeding on her own, and whether her nipples are inverted, everted, or flat. thus, the latch assessment enables the separation of multiple factors that may contribute to breast-feeding failure. a multivariate regression analysis will determine how strongly the probability of breast-feeding at hospital discharge correlates with epidural duration, latch scores, and beta-endorphin concentrations in colostrum.


Eligibility criteria:
inclusion criteria: * age 18 or over * vaginal delivery of a single live neonate at metrohealth medical center's main campus exclusion criteria: * delivery by caesarean section * admission to the nicu following delivery * neonatal or maternal pathologies that would obviously impede normal breast-feeding activity

Keywords: epidural beta-endorphins breast-feeding colostrum feeding
effects of alpha-acid lipoic in pcos women

Conditions: Polycystic Ovary Syndrome

Summary: the aim of our study is to investigate the effects of six months treatment with alpha-lipoic acid on clinical, endocrine and metabolic features in women affected by pcos. menstrual pattern, anthropometric parameters, hirsutism score, ultrasound ovarian featureas, an oral glucose tolerance test and hormonal assays are evaluated before and after therapy.


Eligibility criteria:
inclusion criteria: * women with pcos in accordance with rotterdam criteria exclusion criteria: * pregnancy * past history of cardiovascular diseases * diabetes mellitus (or impaired glucose tolerance as determined by a standard 75 gr oral glucose tolerance test) * hypertension * significant liver or renal impairment * other hormonal dysfunction (hypothalamic, pituitary, thiroidal or adrenal) * neoplasms.
co2 laser therapy for the treatment of gsm in patients with breast cancer

Conditions: Breast Cancer; Genitourinary Syndrome of Menopause

Summary: given the need for an effective, non-hormonal treatment for genitourinary syndrome of menopause gsm) symptoms in breast cancer survivors, the reported efficacy of fractional co2 laser as such a treatment in retrospective studies, the study aims to evaluate the efficacy of co2 laser for the treatment of gsm in breast cancer patients, in a prospective, randomized, blinded, placebo-controlled trial.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with breast cancer 2. menopause: spontaneous, surgical or chemotherapy induced 3. one or more gsm symptoms: dryness, irritation, burning, pain, dyspareunia, dysuria 4. on exam, clinical findings of atrophy: thin, dry, pale vagina 5. age\>18 6. normal pap smear within 3 years exclusion criteria: 1. menstruation 2. chemotherapy 3. vaginal bleeding which did not underwent evaluation 4. concurrent treatment with topical estrogen 5. previous vulvar, vaginal or cervical dysplasia\\ cancer
dd obesity mri study

Conditions: Diverticular Disease

Summary: in this study, our novel mri techniques for studying the small bowel will be applied to patients with diverticular disease. the ratio of visceral to subcutaneous fat will also be determined using mri measurements. these data will be correlated with measurements of adipokines to determine if visceral fat has a specific influence on the severity of diverticular disease.

colonic diverticulosis is the most common structural abnormality of the colon and studies suggest that its incidence and/or complications are increasing. increasing evidence suggests a link between obesity and complications of diverticular disease. with the prevalence of obesity increasing in westernised populations, the risk of complications from diverticular disease is likely to also increase. at present however, there is little understanding of how diverticular complications are increased by obesity. a high bmi might be a surrogate marker for other lifestyle factors which predispose to diverticular complications. visceral fat may also have an influence on related complications, due to the compounds secreted by adipocytes. altered bowel habit is a common complaint of diverticular patients. the cause is not well understood, is probably multi-factorial, and may include changes in the small bowel. until recently, studies of the large and small bowel required intestinal intubation and perfusion and could not be performed on the undisturbed colon. new mri techniques have now been developed, which allow these areas to be studied non-invasively. abdominal fat can also be measured using mri, and the distribution of subcutaneous and visceral fat will be compared for symptomatic and asymptomatic diverticular patients.

Eligibility criteria:
inclusion criteria: * participants must have symptomatic and asymptomatic diverticular disease confirmed on colonoscopy, barium enema or ct scan (symptomatic disease is defined as lower abdominal pain \>1hr on 3 or more days per month for longer than 3 months.) exclusion criteria: * 1. pregnant or lactating women. 2. severe co-morbidity; e.g. heart failure, respiratory failure, alcoholism or drug dependence, 3. inability to give informed consent. 4. if the participant has taken part in any other study on campus in the last 3 months they will not be able to take part in this study. 5. inability to lie supine 6. inability to stop laxatives for 24hrs and antispasmodics or ondansetron for 8 hours prior to the commencement of the mri study. 7. using long-term nsaids (non-steroidal anti-inflammatory agents e.g. ibuprofen), antibiotics or immunosuppressant drugs 8. antibiotics within last 3 months 9. other gastrointestinal inflammatory problems e.g. ulcerative colitis, crohn's or coeliac disease mri exclusions 10. have a metallic implant 11. have shrapnel inside the body 12. ever had metallic fragments in the eye 13. claustrophobia

Keywords: diverticular disease mri visceral and subcutaneous fat adipokines
evaluation of performance characteristics of capsule endoscopy with pillcam ugi capsule compared to standard endoscopy

Conditions: Barrett Esophagus

Summary: this study is to examine the benefits of newly designed capsule with enhanced frame rate and wide angle compared to standard endoscopy, which may help enhance detecting esophageal diseases that otherwise may have been out of vision in the standard endoscopy, ultimately decreasing healthcare costs.

this is a pilot, single center, prospective, tandem study. all veteran patients with barrett's esophagus scheduled for an upper egd at veterans affairs medical center (kansas city, mo, usa) for check-up of be will be asked to swallow the pillcam prior to an egd. a member of the research team will approach a potential subject to discuss participation in the study, including background of the proposed study, inclusion and exclusion criteria, benefits and risks of the procedures and follow-up. if this is of interest to the subject, the informed consent form is discussed and presented. the subject must sign the consent form prior to enrollment. this form will have prior approval of the study site's institutional review board (irb). failure to obtain informed consent renders the subject ineligible for the study eligible subjects at the participating institution who meet the inclusion criteria for this study will be offered the opportunity to participate in this clinical trial. to ensure that subjects are approached for potential study participation without bias, a subject screening log will be maintained. this log will track the basic demographic information of each subject approached for clinical trial inclusion and the resulting reason for exclusion from the clinical study if applicable. the duration of the study is expected to be approximately 12 months. enrollment of study patients will cease when approximately 20 patients have been enrolled.

Eligibility criteria:
inclusion criteria: * patients age: ≥ 18 years * patients with be length ≥ 1cm undergoing upper endoscopy * willingness to undergo both unsedated, capsule endoscopy and conventional egd * ability to provide written, informed consent and understand the responsibilities of trial participation exclusion criteria: * coagulopathy with inr \> 1.5, thrombocytopenia with platelet counts \< 50,000 * pregnant or planning a pregnancy during the study period * dysphagia * known esophageal diverticulum or stricture * swallowing disorder * known luminal, gastrointestinal stricture * history of esophageal, gastric surgery * esophageal or gi motility disorder * subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines * known or suspected gastrointestinal obstruction, strictures, or fistulas based on the clinical picture or pre-procedure testing and profile. * subjects with cardiac pacemakers or other implanted electromedical devices. * anticipated magnetic resonance imaging within 1 week of capsule ingestion
iron deficiency as an ignored cause of infertility

Conditions: Iron Deficiency; Infertility

Summary: iron deficiency may play a critical role in human infertility, oocyte quality and may even play a role in endometrial receptivity. by correcting iron deficiency, low ferritin values, in infertile women with intravenous iron supplementation, embryo quality and pregnancy rates may improve. the main objective is to evaluate the effect of intravenous iron supplementation on embryo quality (number of good quality blastocysts). randomized, double blind, parallel group, cross-over study of ferric carboxymaltose compared to placebo (nacl infusion).


Eligibility criteria:
inclusion criteria: * patient's 18 to 42 years and in full consent * ferritin ≤ 30 ug/l * anti-mullerian hormone (amh) \> 1ug/l * planned for ivf/ icsi treatment * diagnosis for treatment: tubal factor, male factor or unexplained infertility (nud) exclusion criteria: * endometriosis * poor responder * inflammatory bowel disease (ibd), colitis ulcerosa * rheumatoid arthritis * renal insufficiency * cardiac insufficiency * body mass index (bmi) over 35 * known hypersensitivity to the active substance, to ferric carboxymaltose or any of its excipients, or to other parental iron products * clinical evidence of iron overload or disturbances in the utilization of iron * use of atosiban or filgrastim during stimulation or embryo transfer

Keywords: low ferritin infertility in vitro fertilization (ivf) intracytoplasmic sperm injection (icsi) assisted reproductive technology (art)
favor opioid recovery coaching evaluation

Conditions: Opiate Abuse; Opiate Overdose; Opioid-use Disorder

Summary: the emergency department (ed) is an ideal location to identify patients in need of treatment for opioid addiction. a local non-profit community-based addiction recovery program, faces and voices of recovery (favor) utilizes a peer recovery coaching model applied to substance use disorders by identifying, training, credentialing and supervising individuals who have been in recovery for at least 2 years. these peer recovery coaches become the primary workforce in this community-based model. favor provides no-cost comprehensive services for addiction recovery. the investigators hypothesized that having favor recovery coaches (frc) evaluate patients during an ed visit for opioid overdose would result in a high degree of engagement from the patients and serve as an opportunity to begin treatment for addiction.

the emergency department (ed) is an ideal location to identify patients in need of treatment for opioid addiction. a local non-profit community-based addiction recovery program, faces and voices of recovery (favor) utilizes a peer recovery coaching model applied to substance use disorders by identifying, training, credentialing and supervising individuals who have been in recovery for at least 2 years.these peer recovery coaches become the primary workforce in this community-based model. favor provides no-cost comprehensive services for addiction recovery. the investigators hypothesized that having favor recovery coaches (frc) evaluate patients during an ed visit for opioid overdose would result in a high degree of engagement from the patients and serve as an opportunity to begin treatment for addiction.

Eligibility criteria:
inclusion criteria: * patients presenting to the ed with opioid overdose or withdrawal exclusion criteria: * age \<18 * known pregnant female * prisoners

Keywords: opioid overdose